Armand Glassman to Imatinib Mesylate
This is a "connection" page, showing publications Armand Glassman has written about Imatinib Mesylate.
Connection Strength
0.032
-
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood. 2005 Mar 15; 105(6):2281-6.
Score: 0.016
-
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol. 2004 Apr; 125(2):187-95.
Score: 0.015